Moolec Science (MLEC) Income from Discontinued Operations (2023 - 2024)
Moolec Science (MLEC) reported Income from Discontinued Operations of 280889.0 for Q4 2024, down 219.03% on a YoY basis from 235990.0 in Q1 2024, and down 1103.57% sequentially from 27989.0 in Q3 2024.
Moolec Science (MLEC) Income from Discontinued Operations (2023 - 2024) Analysis & Trends
Moolec Science (MLEC) has 2 years of Income from Discontinued Operations data on file, last reported at 280889.0 in Q4 2024.
- For the quarter ending Q4 2024, Income from Discontinued Operations fell 219.03% year-over-year to 280889.0; the trailing twelve-month figure through Dec 2024 stood at 342804.0 (changed N/A YoY), and the FY2024 full-year result was 1046985.0, up 346.4% from the prior year.
- Income from Discontinued Operations declined to 280889.0 in Q4 2024, from 27989.0 in the prior quarter.
- In the past five years, Income from Discontinued Operations ranged from a high of 722654.0 in Q2 2024 to a low of 280889.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | - |
| 2 | Nanobiotix | 1,935.05 Bn | 1,934.98 Bn | - | - |
| 3 | Akari Therapeutics | 1,021.31 Bn | 1,021.31 Bn | - | - |
| 4 | BeOne Medicines | 467.89 Bn | 463.10 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.95 Bn | 115.70 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.19 Bn | 61.44 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 63.46 Bn | 63.46 Bn | - | - |
| 8 | Argenx Se | 55.64 Bn | 50.45 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.67 Bn | 34.66 Bn | 959.66 Mn | - |
| 10 | Moolec Science | 5.21 Bn | 5.21 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -280,889.00 |
| Sep 30, 2024 | 27,989.00 |
| Jun 30, 2024 | 722,654.00 |
| Mar 31, 2024 | -126,950.00 |
| Dec 31, 2023 | 235,990.00 |
| Sep 30, 2023 | 215,291.00 |